New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Lisata Therapeutics, Inc. (LSTA) vs TScan Therapeutics, Inc. (TCRX)
- Lisata Therapeutics, Inc. LSTA 0.90 −1.10%
- TScan Therapeutics, Inc. TCRX 0.15 +7.14%
Lisata Therapeutics, Inc. and TScan Therapeutics, Inc. are both Biotechnology companies. Lisata Therapeutics, Inc. and TScan Therapeutics, Inc. are of similar size ($9.8M and $9.4M). Lisata Therapeutics, Inc. grew revenue faster over the last twelve months: 57.2% against −38.4%. Lisata Therapeutics, Inc. has the higher net margin (−274.9% vs −2,219.2%) and the higher return on invested capital (0.00% vs 0.00%). Across the 17 metrics below, Lisata Therapeutics, Inc. leads on 13 and TScan Therapeutics, Inc. on 4.
Valuation
Profitability
| Metric | LSTA | TCRX | Biotechnology median |
|---|---|---|---|
| Gross margin | 14.13% | 100.00% | 70.18% |
| Operating margin | (398.56%) | (2,246.84%) | 0.00% |
| Net margin | (274.88%) | (2,219.19%) | 0.00% |
| Free cash flow margin | (137.78%) | (2,152.72%) | 0.00% |
| Return on equity | (138.59%) | (126.45%) | (51.58%) |
| Return on assets | (5.12%) | (57.03%) | (45.91%) |
| Return on invested capital | 0.00% | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack